Press Releases
Cell Signaling Technology Announces Pilot Study for Chiron Corporation to Evaluate CST’s PhosphoScan® Platform for Kinase Inhibitor Phosphoproteomic Profiling
Beverly, MA, May 31, 2005 – Cell Signaling Technology, Inc. (CST) announced today an agreement with Chiron Corporation to perform a pilot study employing CST’s PhosphoScan® technology to identify phosphorylation sites and prospective biomarkers of protein tyrosine kinase (PTK) targets. CST’s PhosphoScan® phospho-proteomics technology enables the determination of cellular PTK phospho-profiles (Phospho-Signatures®) and can provide direct insight into disease mechanisms and kinase target function. It is based on patent-pending methodologies combining immunoaffinity purification and mass spectroscopy. The phospho-profiles discovered with PhosphoScan® may enable biomarker assays for target validation and kinase inhibitor pharmacodynamics and efficacy. The PhosphoScan® technology was recently described in the journal, Nature Biotechnology (Rush J. et al, Nat. Biotechnol. 23, 94-101 (2005)).
“CST is excited about the opportunity to apply its PhosphoScan® technology within the context of Chiron’s oncology therapeutic programs to phospho-profile kinase target activation and inhibition, which CST believes could provide information valuable to Chiron,” said Christopher Bunker, CST’s Director of Business Development.
About Cell Signaling Technology, Inc.
Cell Signaling Technology, Inc. has expertise and the market leadership position in the development and commercialization of phospho-specific antibodies and assays for kinase and pathway analysis. CST’s phospho-specific antibodies are validated in multiple assay platforms and are critical reagents in all stages of pharmaceutical drug discovery and development. CST has leveraged its antibody core capabilities to develop PhosphoScan®, a superior phospho-proteomics platform to enable more efficient and informative kinase drug discovery and clinical development. CST’s extensive experience using PhosphoScan® has yielded in-depth tyrosine kinase Phospho-Signatures®, and with CST’s expertise in immunoassay development, CST can translate information from PhosphoScan® into validated biomarker assays. CST is commercializing the PhosphoScan® technology through research alliances and licensing opportunities. Information on CST can be obtained at the Company’s website at www.cellsignal.com
For more information, contact:
Christopher Bunker, Ph.D.
Cell Signaling Technology, Inc.
Director of Business Development
phone: (978) 867-2307
e-mail: cbunker@cellsignal.com
